Sep. 29, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GMO Global Developed Equity Allocation Fund | GMO Global Developed Equity Allocation Fund | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investment objective | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Total return greater than that of its
benchmark, the MSCI World Index.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fees and expenses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
The table below describes the fees and
expenses that you may bear for each class of shares if you buy, hold, and sell shares of the Fund. You
may pay other fees, such as brokerage commissions and other fees to financial intermediaries, which are not reflected in the table and
example below.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Annual Fund operating expenses (expenses that you bear each year as a percentage of the value of your investment) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1
Includes both management fee and class-specific service and supplemental support fee, if any.
2
Because ETF Class shares of the Fund are new, “Other expenses” are estimated amounts for
the current fiscal year based on the expenses of Class R6 shares of the Fund.
3
Because ETF Class shares of the Fund are new, “Acquired fund fees and expenses” are estimated
amounts for the current fiscal year based on the expenses of Class R6 shares of the Fund.
4
Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) has contractually agreed to reimburse
the Fund for the following expenses: audit expenses, fund accounting and administration expenses, pricing service expenses, expenses of
non-investment related tax services, transfer agency expenses (excluding, in the case of Class I shares, any amounts paid for sub-transfer
agency, recordkeeping and other administrative services provided by financial intermediaries for the benefit of Class I shareholders),
expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses,
printing expenses, state and federal registration fees, custody expenses and exchange listing fees. This reimbursement will continue through
at least September 30,
2027 and may not be terminated prior to this date without the action or consent of the Trust’s Board of Trustees.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Example | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
This example is intended to help you
compare the cost of investing in the Fund with the cost of investing in other funds. The example assumes that you invest $10,000 in the
Fund for the time periods indicated, regardless of whether or not you sell your shares at the end of such periods. The example also assumes
that your investment has a 5% return each year and that the Fund’s operating expenses with respect to ETF Class shares remain the
same as those shown in the table. The one year amounts shown reflect the expense reimbursement noted in the expense table. Although your
actual costs may be higher or lower, based on these assumptions your costs would be:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Portfolio turnover | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
The Fund pays transaction costs, such
as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, for holders
of Fund shares subject to U.S. taxes, higher income taxes. These transaction costs, which are not reflected in Annual Fund operating expenses
or in the Example, affect the Fund’s performance. During its fiscal year ended February 28, 2026, the Fund’s portfolio
turnover rate (excluding short-term investments) was 19%
of the average value of its portfolio securities.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Principal investment strategies | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
The Fund is a fund of funds and invests
primarily in equities traded in U.S. and non-U.S. markets (including emerging markets) through its investment in the Equity Funds and
in GMO-managed exchange-traded funds (collectively, the “underlying GMO Funds”) (see “Additional Information
About the Funds’ Investment Strategies, Risks, and Expenses — Asset Allocation Funds”). The Fund also
may invest directly in securities (including other underlying funds) and derivatives.
GMO
uses its quantitative multi-year forecasts of returns among asset classes, together with its assessment of the relative risks of asset
classes, to determine the asset classes in which the Fund invests and how much the Fund invests in each asset class. An important component
of those forecasts is GMO’s expectation that valuations ultimately revert to their fundamental fair (or intrinsic) value over a
complete market cycle. GMO changes the Fund’s asset class exposures in response to changes in GMO’s investment outlook and
its assessment of market valuations and may use redemptions or purchases of Fund shares to rebalance the Fund’s investments. The
factors GMO considers and investment methods GMO uses can change over time.
Under
normal circumstances, the Fund invests (including through its investment in the underlying GMO Funds) at least 80% of its assets in equities
(see “Name Policies”). In addition, under normal circumstances, the Fund invests (including through its investment in the
underlying GMO Funds) at least 80% of its assets in equities tied economically to developed markets (see “Name Policies”).
The term “developed markets” means
those countries included in the MSCI World Index, a global developed markets equity index, and countries with similar characteristics
(e.g., countries that have sustained economic development, sufficient liquidity for listed companies and accessible markets).
The Fund also may obtain exposure to equities tied economically to emerging markets (which are not part of the Fund’s benchmark),
but those investments typically will represent 10% or less of the Fund’s net assets measured at the time of purchase.
The Fund may invest in securities of
companies of any market capitalization. In addition, the Fund may lend its portfolio securities.
The Fund also may invest in U.S. Treasury
Fund, in money market funds unaffiliated with GMO, and directly in the types of investments typically held by money market funds.
The Fund’s ETF Class operates
as an actively managed exchange-traded fund (“ETF”).
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Performance | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
The
bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Fund’s annual
total returns from year to year for the periods indicated and by comparing the Fund’s average annual total returns for different
calendar periods with those of the Fund’s benchmark, a broad-based securities market index. The
Fund’s ETF Class shares are a new class and, as of the date of this Prospectus, had not commenced operations. Returns
shown are those of Class III shares of the Fund, a mutual fund class of shares of the Fund not offered in this Prospectus, and have
not been adjusted to reflect the fees and expenses attributable to ETF Class shares. Class III shares would have substantially
similar annual returns to ETF Class shares because the shares are invested in the same portfolio of securities, and the annual returns
at NAV (assuming ETF Class shares are bought and sold without any premium or discount) would differ only to the extent that Class III
shares do not have the same expenses as ETF Class shares. Share classes that bear higher expenses than the share classes shown below would
have lower returns. After-tax returns are calculated
using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes.
Actual after-tax returns depend on your tax situation
and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through
tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax
returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information
for the Fund is available at https://www.gmo.com/americas/investment-capabilities/etfs/.
Past performance (before and after taxes) is not an indication
of future performance.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Annual Total Returns/Class III Shares1 Years Ending December 31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Returns include a substantial, one-time litigation settlement recovery received on December 16, 2024. This event contributed 1.42% to 2024 annual performance. 2 Returns include a substantial, one-time performance impact from the sale of Russian securities on May 5, 2026. The one-time sale of these securities contributed 0.37% (1-day performance impact). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Highest
Quarter: 17.63%
2Q 2020
Lowest Quarter: -23.90% 1Q 2020 Year-to-Date: 15.15% As of 6/30/20262 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Annual Total Returns1 Periods Ending December 31, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1
Returns include a substantial, one-time litigation settlement recovery received on December 16,
2024. This event contributed 1.42% to 2024 annual performance.
2
Returns include a substantial, one-time performance impact from the sale of Russian securities on May 5, 2026. The one-time sale
of these securities contributed 0.20% (1-day performance impact).
3
MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not
prepared or approved this report, and has no liability hereunder.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||